Genetic polymorphism of CYP2A6 in relation to cancer.
To clarify the roles of human cytochrome P450 (P450 or CYP) 2A6 and 2E1 on the metabolic activation of N-nitrosamines, we established genetically engineered Salmonella typhimurium strains harboring human CYP2A6 or CYP2E1 together with NADPH-P450 reductase (OR). The 5'-terminus of CYP cDNA was modified to achieve a high-level expression in S. typhimurium. Modified CYP2A6 or CYP2E1 cDNA and native OR cDNA were introduced into a pCW vector. S. typhimurium YG7108 cells were transformed with this vector. The mutagen producing ability of these enzymes for some N-nitrosamines were evaluated using the established S. typhimurium cells. We found that the substrate specificity of CYP2A6 and CYP2E1 was different among mutagens. CYP2A6 was responsible for the metabolic activation of N-nitrosamines possessing relatively long alkyl chains, whereas CYP2E1 was responsible for the metabolic activation of N-nitrosamines with relatively short alkyl chains. It is likely that CYP2A6 gene polymorphism is responsible for the interindividual variability on the cancer susceptibility. We found the whole deletion of CYP2A6 gene as a type of genetic polymorphism in Japanese. Thus, we developed a gene diagnosis method to detect the variant. We evaluated the relationship between the CYP2A6 gene whole deletion and the susceptibility to the lung cancer. The frequency of CYP2A6 gene whole deletion was significantly lower in the lung cancer patients than that of healthy volunteers.
Kamataki
T
T
Laboratory of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, N12W6, Kitaku, Sapporo, Japan. kamataki@pharm.hokudai.ac.jp
Nunoya
K
K
Sakai
Y
Y
Kushida
H
H
Fujita
K
K
D001189:Aryl Hydrocarbon Hydroxylases; D016022:Case-Control Studies; D065637:Cytochrome P-450 CYP2A6; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D017353:Gene Deletion; D015870:Gene Expression; D005787:Gene Frequency; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009152:Mutagenicity Tests; D009251:NADPH-Ferrihemoprotein Reductase / Q000235:genetics; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics*; D011110:Polymorphism, Genetic; D012486:Salmonella typhimurium / Q000235:genetics
D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019392:Cytochrome P-450 CYP2E1; D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6; D009251:NADPH-Ferrihemoprotein Reductase